Dr. Nancy Chan, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York at Stony Brook, School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 123
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2008Medical school: State University of New York at Stony Brook, School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 262360 -
Hematology & Oncology Physician
NY license 262360
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 123
- Services billed
- 249
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 129 | 59 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 43 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in New York, NY | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $6,430 in total to this clinician.
| Daiichi Sankyo Inc. | $5,917 |
|---|---|
| Stemline Therapeutics Inc. | $473 |
| Novartis Pharmaceuticals Corporation | $40.61 |
| Consulting Fee | $5,823 |
|---|---|
| Food and Beverage | $608 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Sep 16, 2025 | Consulting Fee Enhertu · ONCOLOGY | $3,425 |
| Daiichi Sankyo Inc. Sep 16, 2025 | Consulting Fee Enhertu · ONCOLOGY | $1,370 |
| Daiichi Sankyo Inc. Jan 15, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,028 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 8 companies. The companies reported $586,958 in research payments for these studies, mostly to the institutions running them.
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with…
AstraZeneca Pharmaceuticals LP - Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06590857 - STUDY NAME#A Phase 2 Study of KEYTRUDA Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced,Metastatic Breast Cancer Patients# Big Ten Cancer Research Consortium BTCRC-BRE16-042
Merck Sharp & Dohme LLC - A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Daiichi Sankyo Inc. · Completed · NCT04699630 - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.